Mobia Medical is a freshly listed implant company trying to turn a single approved stroke-recovery device into a hospital pathway, and the second-quarter print is the first public test of whether that commercial playbook scales. The May listing put a large cash reserve on the balance sheet and retired the going-concern language that had sat in the registration statement. Revenue more than doubled as new stroke-center programs came online. The equity still trades well below the offering price, which is the market's way of asking whether coverage, not hardware, is the real constraint.
What is moving underneath the headline is a territory machine, not a price machine. Second-quarter revenue reached $14 million as average active territories moved into the mid thirties. The field sold a few hundred implantable pulse generators, and gross margin stayed in the low eighties even after freight and tariff costs hit cost of goods. Selling costs rose almost as fast as revenue, so the operating loss widened in absolute terms. The incremental implant is highly profitable. The incremental salesperson is not, until each territory fills its funnel.
Full-year guidance sits in a band from $54 million to $56 million. That range still describes a company spending more on the commercial organization than it collects in gross profit. Two-year follow-up data in Neurology and a new American Heart Association guideline mention for paired vagus-nerve stimulation are the qualitative events that could loosen prior authorization. Whether those evidence wins convert into commercial-payer coverage, and whether the November Medicare outpatient rule holds the current ambulatory payment classification, is the question the next several prints have to answer.